Highly purified recombinant human insulin (RHI) API and its production method

By protecting lysine residues and performing multiple column purification operations, the content of impurity C in recombinant human insulin was successfully reduced, the problem of difficult removal of impurity C in the prior art was solved, and a highly purified recombinant human insulin API was achieved. Production.

CN113226284BActive Publication Date: 2024-12-03AMPHASTAR PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980077319.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-09-25
Filing Date
2019-09-25
Publication Date
2024-12-03
Estimated Expiration
2039-09-25

AI Technical Summary

Technical Problem

The existing impurity C (acetylated LysB31) is difficult to remove during the production process of recombinant human insulin, resulting in a high content of impurity C in the final product, affecting the purity of the drug.

Method used

By protecting the lysine residues of the single-stranded precursor, enzymatic cleavage and multiple column purification operations, including anion exchange column chromatography and reverse phase high performance liquid chromatography (RP-HPLC), the impurity C content is gradually reduced to 0.1 % or less, achieving the goal of highly purified recombinant human insulin API.

Benefits of technology

High purification of recombinant human insulin was achieved, the impurity C content was reduced to 0.1% or less, and the total impurity content was controlled to 0.8% or less, which improved the purity and quality of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113226284B_ABST
    Figure CN113226284B_ABST
Patent Text Reader

Abstract

A method for producing highly purified recombinant human insulin (RHI) having a purity of 99.0% (w / w) or higher and total impurities (excluding related substances as specified in USP, deamidated Asn) A21 The present invention discloses an API composition of highly purified RHI having a purity of 99.0% (w / w) or more, a total impurity of 0.8% (w / w) or less, and an impurity C of 0.1% (w / w) or less. Also disclosed is an API composition of highly purified RHI having a purity of 99.0% (w / w) or more, a total impurity of 0.8% (w / w) or less, and an impurity C of 0.1% (w / w) or less.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure introduces methods for producing highly purified recombinant human insulin (RHI) and compositions thereof. The highly purified RHI is suitable for use as an active pharmaceutical ingredient (API) of a RHI drug product. Background Art

[0002] Human insulin is a hormone that regulates glucose metabolism. The human insulin protein consists of two polypeptide chains - an A chain of 20 amino acids and a B chain of 30 amino acids, for a total of 51 amino acids. The A and B polypeptide chains are linked by a disulfide bond between the A chain cysteine ​​and the corresponding B chain cysteine ​​paired therewith. The disulfide bond and the corresponding cysteine ​​(Cys) are Cys A7 -Cys B7 、Cys A20 -Cys B19 and Cys A6 -Cys A11 Recombinant human insulin is a proven therapeutic composition for diabetic patients. Diabetes is characterized by elevated blood sugar levels and / or increased hepatic glucose production due to insulin deficiency. Recombinant human insulin can be administered to patients by subcutaneous injection or intravenous injection.

[0003] The basic technology of using recombinant DNA technology to synthesize recombinant human insulin API is well known in the art. However, the technical challenge of implementing these basic technologies into a robust production / synthetic process remains a difficult technical challenge, because in the production process of recombinant human insulin API, different impurities of different types and quantities are produced. Moreover, different pharmaceutical companies may produce different impurities in the production / synthetic process of recombinant human insulin, because different companies can adopt different production process strategies, different starting materials (for example, the sequence of single-chain precursor (SCP) is different), different expression host cells for gene expression, etc. In the present disclosure, "human insulin" or "insulin" can be interchangeable and synonymous with "recombinant human insulin" or "RHI".

[0004] Currently available RHI drug products on the market contain certain levels of impurities. Typical levels of total impurities are in the range of about 1-2% (w / w) (excluding related substances such as deamidated Asn as defined by the United States Pharmacopeia (USP) for RHI). A21 -Human insulin ("deamidated Asn A21-RHI”)), some of these total impurities are generated in the RHI drug product (e.g., solution), which can increase over time, while some of these total impurities are present in the API. Therefore, RHI API with fewer impurities will provide a basis for RHI drug products with fewer impurities. Thus, there is a need in the art for high-purity RHI API. The present disclosure relates to the production of total impurities (excluding related substances deamidated Asn as specified in USP) based on the total weight of RHI API. A21 -RHI) does not exceed 0.8% (w / w) of RHI API, which is hereinafter referred to as "highly purified recombinant human insulin API", or "highly purified RHI API".

[0005] In addition, some impurities may be difficult to remove, such as the acetylated lysine at position 31 of the B chain of RHI (Lys B31 , Lys B31 or K B31 ), referred to herein as "Impurity C" or "Impurity C". In particular, the Impurity C precursor may be as high as about 2-3% (w / w) in the SCP material before it is processed into RHI. An example of an Impurity C precursor is acetylated Lys C1 , which may have been generated during the synthesis of SCP. The synthesis of SCP consisting of A chain, B chain, C peptide and leader sequence can be carried out using a main host cell (i.e., Escherichia coli) through a fermentation method developed by Ferring International Center in Switzerland. See, for example, Ferring's European Patent No. EP0871474B1, entitled "Production of Human Insulin"; application filing date December 29, 1994, authorization date March 1, 2007. The present disclosure seeks to continue and significantly improve on the work done by Ferring, such as significantly reducing total impurities (excluding related substances deamidated Asn as specified in USP). A21 -RHI) and impurity C in order to produce highly purified RHI for use as API.

[0006] Even after several purification operations are applied during the processing of SCP into RHI, impurity C can still be as high as 0.7% (w / w) as an impurity in the final purified RHI API composition. Therefore, in order to produce highly purified RHI API, a technical solution is needed to reduce the amount of impurity C during the production / synthesis process of RHI. Therefore, the present disclosure provides a method for producing a RHI API having a purity of 99.0% (w / w) or higher, total impurities (excluding related substances deamidated Asn) based on the total weight of the RHI API. A21-RHI) of 0.8% or less and impurity C of 0.1% (w / w) or less, solves the technical problem. The present disclosure also provides a method for preparing an RHI API with a purity of 99.0% (w / w) or higher based on the total weight of the RHI API, total impurities (excluding related substances deamidated Asn A21 -RHI) is 0.8% or less and impurity C is 0.1% (w / w) or less. In addition, the present disclosure introduces a composition of RHI API having a purity of 99.0% (w / w) or higher based on the total weight of the RHI API, total impurities (excluding related substances deamidation Asn A21 -RHI) is 0.8% or less, impurity C is 0.1% (w / w) or less, and impurity E is 0.2% (w / w) or less, and a method for producing the RHI API. Summary of the invention

[0007] The exemplary embodiments of the present disclosure solve at least the above-mentioned problems and / or disadvantages, and advance the art by providing at least the advantages described below. Additional objects, advantages and salient features of the exemplary embodiments of the present disclosure will become apparent to those skilled in the art from the following detailed description, which discloses exemplary embodiments of the present disclosure in conjunction with the accompanying drawings.

[0008] Process for producing highly purified RHI API

[0009] First, the present disclosure provides a method for producing a highly purified recombinant human insulin (RHI) active pharmaceutical ingredient (API) having a purity of 99.0% (w / w) or higher, a total impurity of 0.8% or lower, and an impurity C of 0.1% (w / w) or lower based on the total weight of the RHI API. The total impurities do not include deamidated Asn A21 -RHI, and impurity C is acetylated Lys B31 -RHI.

[0010] In a preferred embodiment, the method described in the present disclosure produces a highly purified RHI API in solid form, based on the total weight of the highly purified RHI API in solid form, with a purity of 99.0% (w / w) or more, a total impurity of 0.8% (w / w) or less, and an impurity C of 0.1% (w / w) or less. In other embodiments, the disclosed method produces a RHI API in liquid form, based on the total weight of the RHI API in liquid form, with a purity of 99.0% (w / w) or more, a total impurity of 0.8% (w / w) or less, and an impurity C of 0.1% (w / w) or less. In addition, the disclosed method produces a RHI API in solid or liquid form, based on the total weight of the RHI API, with a purity of 99.0% (w / w) or more, a total impurity (excluding related substances deamidated Asn) or less. A21 -RHI) is 0.8% (w / w) or less, impurity C is 0.1% (w / w) or less, and impurity E is 0.2% (w / w) or less.

[0011] As defined herein, "highly purified recombinant human insulin API" or "highly purified RHI API" refers to a recombinant human insulin API (in solid or liquid form) having a total impurity content of 0.8% (w / w) or less based on the total weight of the RHI API. "Total impurities" or "total impurities" refers to the total impurities of the recombinant human insulin API (in solid or liquid form) other than the related substance deamidated Asn A21 -All impurities in the RHI API other than RHI. For the sake of brevity in this article, an RHI API with a total impurity of 0.8% (w / w) or less based on the total weight of the RHI API is referred to as a "highly purified RHI API". For example, an RHI API with a purity of 99.0% (w / w) or greater, a total impurity of 0.8% (w / w) or less, and an impurity C of 0.1% (w / w) or less based on the total weight of the RHI API is considered to be a "highly purified RHI API". As will be described herein, a highly purified RHI API is a highly purified RHI API produced using the method described in the present disclosure. The USP Guidelines on RHI stipulate that the total impurities of RHI do not include the related substance deamidated Asn A21 -RHI.

[0012] In some embodiments, a method for producing a highly purified RHI API comprises:

[0013] Two lysine residues on the single-chain precursor (SCP) are protected with lysine protecting groups, wherein SCP has the structural formula [(leader peptide)-(B chain)-(C peptide)-(A chain)], wherein the C peptide is composed of Arg C2-Lys C1 The two lysine residues are the first lysine residue (Lys C1 ), and the second lysine residue at residue 29 (B29) of the B chain of SCP (Lys B29 );

[0014] Enzymatic cleavage of SCP to generate Arg C2 -Lys C1 -RHI;

[0015] The first column purification operation was applied to remove Arg C2 -Lys C1 -RHI to separate the leader peptide, thereby generating Arg C2 -Lys C1 -RHI;

[0016] Half-cleavage of Arg C2 -Lys C1 -C peptide in RHI to generate Lys C1 -RHI and impurity C, wherein impurity C is acetylated Lys B31 -RHI;

[0017] Make Lys C1 - Deprotection of the two lysine residues in RHI;

[0018] A second column purification operation was performed to remove Lys C1 - Separation of one or more impurities from RHI;

[0019] Lys C1 -RHI applied a third column purification operation to remove Lys C1 -The amount of impurity C in RHI is reduced to Lys C1 - 0.1% (w / w) or less of the total weight of RHI;

[0020] Lys C1 -RHI to generate Lys C1 and RHI; applying a fourth column purification operation to separate one or more impurities from the RHI, thereby producing highly purified RHI for use as an API; and

[0021] crystallizing the highly purified RHI API to produce the highly purified RHI API in solid form;

[0022] The method produces a highly purified RHI API in solid form having a purity of 99.0% (w / w) or higher and a total impurity of 0.8% (w / w) or lower, wherein the total impurity does not include deamidated AsnA21 - RHI, and impurity C is 0.1% (w / w) or less, wherein w / w means weight to weight and is based on the total weight of the highly purified RHI API in solid form.

[0023] In other embodiments, the method produces a highly purified RHI API in solid form having a purity of 99.3% (w / w) or greater, a total impurity of 0.5% (w / w) or less, and an impurity C of 0.1% (w / w) or less, all based on the total weight of the highly purified RHI API in solid form. The purity and impurity percentage (w / w) of the highly purified RHI API in solid form can be assessed soon after the highly purified RHI API is crystallized into a solid form, for example, within 6, 12, 24, 48 or 72 hours after the highly purified RHI API is crystallized into a solid form.

[0024] In other embodiments, the method can produce a highly purified RHI API in liquid form having a purity of 99.3% (w / w) or more, a total impurity of 0.5% (w / w) or less, and an impurity C of 0.1% (w / w) or less, based on the total weight of the highly purified RHI API in liquid form. The purity and impurity percentage (w / w) of the highly purified RHI API in liquid form can be assessed soon after the last purification operation, for example, within 6, 12, 24, 48, or 72 hours after the last purification operation. Operation 111 in method 100 is an exemplary embodiment of such a last purification operation. In some embodiments of the disclosed methods, SCP is cleaved to produce Arg C2 -Lys C1 -RHI involves the application of trypsin to Arg C2 -Lys C1 -RHI. In some embodiments of the method, the enzyme cleaves Arg C2 -Lys C1 -RHI to generate Lys C1 -RHI and impurity C step includes the addition of Arg C2 -Lys C1 -RHI uses carboxypeptidase B (CPB). In some embodiments of the method, the enzyme cleaves Lys C1 -RHI to produce RHI also includes the step of adding Lys C1 - RHI applies CPB.

[0025] In some embodiments of the method, the first column purification operation utilizes anion exchange column chromatography. In some embodiments of the method, the second column purification operation utilizes anion exchange column chromatography. In other embodiments of the method, the third column purification operation utilizes RP-HPLC to separate Lys C1 -The amount of impurity C in RHI is reduced to Lys C1 -0.1% (w / w) or less of the total weight of RHI, which in turn enables the production of a highly purified RHI API having an impurity C of 0.1% (w / w) or less based on the total weight of the highly purified RHI API, as described herein. In other embodiments of the method, the fourth column purification operation utilizes RP-HPLC.

[0026] In some embodiments, the third column purification operation and the fourth column purification operation each use RP-HPLC. In some embodiments, the third column purification operation and the fourth column purification operation each use RP-HPLC with a C18 column. In other embodiments, the third column purification operation and the fourth column purification operation each use RP-HPLC with a C8 column.

[0027] In some embodiments of the method, Lys C1 The third column purification operation to reduce the amount of impurity C in RHI to 0.1% (w / w) or less includes applying reverse phase high performance liquid chromatography (RP-HPLC) using a C18 column to separate Lys C1 -RHI to separate impurity C. In other embodiments of the method, the third column purification operation also includes using an aqueous solution containing (NH4)2SO4, isopropyl alcohol (IPA) or a combination thereof in RP-HPLC. In other embodiments of the method, the third column purification operation also includes applying a pH of about 2.5 to about 3.0 in RP-HPLC. In some embodiments of the method, the third column purification operation utilizes RP-HPLC with a preparative column, such as a preparative column with a length of about 250 mm and an inner diameter of about 10.0 mm. In other embodiments of the method, the third column purification operation further utilizes RP-HPLC with a semi-preparative column, such as a preparative column with a length of about 250 mm and an inner diameter of about 21.2 mm.

[0028] In some embodiments, the method further comprises renaturing the SCP using a renaturation buffer. In other embodiments, the method further comprises optionally removing trypsin using aprotinin.

[0029] In some embodiments, the one or more impurities separated by the second column purification operation include at least Arg C2In some embodiments, the one or more impurities separated by the fourth column purification operation include at least Lys C1 In each column purification operation, the one or more impurities separated may include those known in the art as well as those identified herein, including the impurities identified in Tables 1-6. It is worth noting that the separation of impurities may include the type of impurity, the amount of impurity, or a combination thereof.

[0030] In other embodiments, the method for producing a highly purified RHI API comprises:

[0031] At least two lysine residues on the single-chain precursor (SCP) are protected with lysine protecting groups, wherein the SCP has a structural formula of [(leader peptide)-(B chain)-(C peptide)-(A chain)], wherein the C peptide contains at least Arg C2 -Lys C1 , wherein the lysine residue comprises the first lysine residue (Lys C1 ), and the second lysine residue at residue 29 (B29) of the B chain of SCP (Lys B29 );

[0032] Enzyme cleavage Arg C2 -Lys C1 -RHI to generate Lys C1 -RHI and impurity C, wherein impurity C is acetylated Lys B31 -RHI;

[0033] Make Lys C1 - Deprotection of lysine residues in RHI;

[0034] Multiple column purification operations are applied to produce highly purified RHI for use as an API, wherein at least one of the column purification operations removes Lys C1 -The amount of impurity C in RHI is reduced to Lys C1 - 0.1% (w / w) or less of the total weight of RHI;

[0035] Lys C1 -RHI to produce RHI; and

[0036] crystallizing the highly purified RHI API to produce the highly purified RHI API in solid form;

[0037] The method produces a highly purified RHI API in a solid form having a purity of 99.0% (w / w) or higher and a total impurity of 0.8% (w / w) or lower, wherein the total impurity does not include deamidated Asn A21- RHI, and impurity C is 0.1% (w / w) or less, wherein w / w means weight to weight and is based on the total weight of the highly purified RHI API in solid form.

[0038] In other embodiments, the method for producing highly purified recombinant human insulin (RHI) comprises:

[0039] At least two lysine residues on the single-chain precursor (SCP) are protected with lysine protecting groups, wherein the SCP has a structural formula of [(leader peptide)-(B chain)-(C peptide)-(A chain)], wherein the C peptide contains at least Arg C2 -Lys C1 , wherein the lysine residue comprises the first lysine residue (Lys C1 ), and the second lysine residue at residue 29 (B29) of the B chain of SCP (Lys B29 );

[0040] Enzyme cleavage Arg C2 -Lys C1 -RHI to generate Lys C1 -RHI and impurity C, wherein impurity C is acetylated Lys B31 -RHI;

[0041] Make Lys C1 - Deprotection of lysine residues in RHI;

[0042] Multiple column purification operations are applied to produce highly purified RHI for use as an API, wherein at least one of the column purification operations removes Lys C1 -The amount of impurity C in RHI is reduced to Lys C1 - 0.1% (w / w) or less of the total weight of RHI; and

[0043] Lys C1 -RHI to produce RHI;

[0044] The method produces a high purity RHI API in liquid form having a purity of 99.0% (w / w) or higher and a total impurity of 0.8% (w / w) or lower, wherein the total impurity does not include deamidated Asn A21 - RHI, and impurity C is 0.1% (w / w) or less, wherein w / w means weight to weight and is based on the total weight of the highly purified RHI API in liquid form.

[0045] In some embodiments, the multiple column purification operations include:

[0046] From Arg C2 -LysC1 - at least a first column purification operation to separate the leader peptide sequence in RHI, wherein the first column purification operation occurs after the enzymatic cleavage of SCP to produce Arg C2 -Lys C1 -RHI step, but after the cleavage of Arg C2 -Lys C1 -RHI to generate Lys C1 - Before the step of RHI and impurity C;

[0047] From Lys C1 -At least Arg is separated in RHI C2 The second column purification operation, wherein the second column purification operation is carried out by using Lys C1 - separation of one or more impurities after a step of deprotection of lysine residues in RHI;

[0048] The third column purification operation was to convert Lys C1 - said column purification operation in which the amount of impurity C in RHI is reduced to 0.1% (w / w) or less, and the third column purification operation occurs after Lys C1 -RHI is followed by the deprotection step of lysine residues, but the enzyme cleaves Lys C1 - RHI before the step of generating RHI; and

[0049] Separation of at least Lys from RHI C1 The fourth column purification operation, wherein the fourth column purification operation occurs at the enzymatic cleavage of Lys C1 -After the RHI step.

[0050] In addition, the disclosed method further reduces the amount of impurity E to 0.2% (w / w) or less, and impurity E is Thr B30 Delete-RHI, thereby producing a highly purified RHI API in solid form or liquid form, with a purity of 99.0% (w / w), total impurities of 0.8% (w / w) or less, impurity C of 0.1% (w / w) or less, and impurity E of 0.2% (w / w) or less, based on the total weight of the highly purified RHI API in solid form or liquid form, respectively. In other embodiments, the method produces a highly purified RHI API in solid form or liquid form, with a purity of 99.3% (w / w) or more, total impurities of 0.5% (w / w) or less, impurity C of 0.1% (w / w) or less, and impurity E of 0.2% (w / w) or less, wherein w / w represents the weight to weight of the API, and is based on the total weight of the highly purified RHI API in solid form or liquid form, respectively.

[0051] In some embodiments, the disclosed methods reduce the amount of impurity C to 0.1% (w / w) or less, including but not limited to 0.09% (w / w) or less, 0.08% (w / w) or less, 0.07% (w / w) or less, 0.06% (w / w) or less, 0.05% (w / w) or less, 0.04% (w / w) or less, 0.03% (w / w) or less, 0.02% (w / w) or less, 0.01% (w / w) or less, or not detected, based on the total weight of the highly purified RHI API. In other embodiments, impurity C is acetylated Lys B31 -RHI. In yet other embodiments, impurity C includes acetylated Lys B31 -RHI.

[0052] In other embodiments, the disclosed methods reduce the amount of impurity E to 0.25% (w / w) or less based on the total weight of the highly purified RHI API, including but not limited to 0.24% (w / w) or less, 0.23% (w / w) or less, 0.22% (w / w) or less, 0.21% (w / w) or less, 0.20% (w / w) or less, 0.19% (w / w) or less, 0.18% (w / w) or less, 0.17% (w / w) or less, 0.16% (w / w) or less, 0.15% (w / w) or less. ) or less, 0.14% (w / w) or less, 0.13% (w / w) or less, 0.12% (w / w) or less, 0.11% (w / w) or less, 0.10% (w / w) or less, 0.09% (w / w) or less, 0.05% (w / w) or less, 0.04% (w / w) or less, 0.03% (w / w) or less, 0.02% (w / w) or less, 0.01% (w / w) or less, or not detected.

[0053] Composition of highly purified RHI API

[0054] Second, the present invention also provides a composition for an active pharmaceutical ingredient (API), comprising highly purified recombinant human insulin (RHI) in solid or liquid form, having a purity of 99.0% (w / w) or higher, 0.8% (w / w) or lower total impurities and 0.1% (w / w) or lower impurity C, wherein w / w represents the weight to weight of the API and is based on the total weight of the highly purified RHI API in solid or liquid form, respectively. As disclosed herein, the total impurities do not include the related substance deamidated Asn A21 -RHI - , impurity C is acetylated Lys B31 -RHI.

[0055] In some embodiments of the composition, the purity of the highly purified RHI API in solid or liquid form is 99.3% (w / w) or higher, the total impurities are 0.5% (w / w) or lower, and the impurity C is 0.1% (w / w) or lower, wherein w / w represents the weight to weight of the API and is based on the total weight of the highly purified RHI API in solid or liquid form, respectively.

[0056] In still other embodiments of the composition, the purity of the highly purified RHI API in solid or liquid form is 99.0% (w / w) or more, the total impurities are 0.8% (w / w) or less, the impurity C is 0.1% (w / w) or less, and the impurity E is 0.2% (w / w) or less, wherein w / w represents the weight to weight of the API and is based on the total weight of the highly purified RHI API in solid or liquid form, respectively. In other embodiments of the composition, the purity of the highly purified RHI API in solid or liquid form is 99.3% (w / w) or more, the total impurities are 0.5% (w / w) or less, the impurity C is 0.1% (w / w) or less, and the impurity E is 0.2% (w / w) or less, wherein w / w represents the weight to weight of the API and is based on the total weight of the highly purified RHI API in solid or liquid form, respectively.

[0057] In some embodiments, the API composition is in solid form. The purity and impurity percentage (w / w) of the highly purified solid RHI API can be quickly evaluated after the highly purified liquid RHI API is crystallized into a solid form, such as within 6, 12, 24, 48 or 72 hours after the highly purified liquid RHI API is crystallized into a solid form. In other embodiments, the highly purified RHI API composition is in liquid form, such as an aqueous form. The purity and impurity percentage (w / w) of the highly purified liquid RHI API can be quickly evaluated after the last purification operation, such as within 6, 12, 24, 48 or 72 hours after the last purification operation. An exemplary embodiment of the last purification operation is operation 111 in method 100. Exemplary embodiments of these highly purified RHI API compositions are provided in Examples 1-8, and these API compositions can be produced using method 100. The disclosed highly purified RHI API compositions can be used for RHI drug products, such as RHI aqueous solutions for subcutaneous or intravenous injections.

[0058] In still other embodiments of the composition, the amount of impurity C of the highly purified RHI API is 0.1% (w / w) or less, including but not limited to 0.09% (w / w) or less, 0.08% (w / w) or less, 0.07% (w / w) or less, 0.06% (w / w) or less, 0.05% (w / w) or less, 0.04% (w / w) or less, 0.03% (w / w) or less, 0.02% (w / w) or less, 0.01% (w / w) or less, or not detected, based on the total weight of the highly purified RHI API.

[0059] In other embodiments of the composition, the amount of impurity E in the highly purified RHI API is 0.25% (w / w) or less, including but not limited to 0.24% (w / w) or less, 0.23% (w / w) or less, 0.22% (w / w) or less, 0.21% (w / w) or less, 0.20% (w / w) or less, 0.19% (w / w) or less, 0.18% (w / w) or less, 0.17% (w / w) or less, 0.16% (w / w) or less, 0.15% (w / w) or less, based on the total weight of the highly purified RHI API. w) or less, 0.14% (w / w) or less, 0.13% (w / w) or less, 0.12% (w / w) or less, 0.11% (w / w) or less, 0.10% (w / w) or less, 0.09% (w / w) or less, 0.05% (w / w) or less, 0.04% (w / w) or less, 0.03% (w / w) or less, 0.02% (w / w) or less, 0.01% (w / w) or less, or not detected. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] The above and other exemplary features and advantages of certain exemplary embodiments of the present disclosure will become more apparent from the following description of certain exemplary embodiments thereof when taken in conjunction with the accompanying drawings, in which:

[0061] Figure 1 is a process flow diagram illustrating an exemplary embodiment of the disclosed method for producing a highly purified RHI API, depicted as method 100 .

[0062] Figure 2, which includes Figure 2A , 2B , 2C, 2D, 2E, 2F, 2G and 2H, describe the processing of SCP and proinsulin into highly purified RHI API according to embodiments of the present disclosure.

[0063] Figure 3 is a process flow diagram of Comparative Example 1 describing a method for producing a lower purity RHI API.

[0064] Figure 4 is a process flow diagram of Comparative Example 2 describing a method for producing a lower purity RHI API.

[0065] Figure 5 is a process flow diagram of Comparative Example 3 describing a method for producing a lower purity RHI API.

[0066] Throughout the drawings, the same drawing reference numerals will be understood to refer to the same elements, features, and structures. DETAILED DESCRIPTION

[0067] With reference to the accompanying drawings, the contents illustrated in the present disclosure are provided to assist in a comprehensive understanding of the exemplary embodiments of the present disclosure. Although the present disclosure has been described in conjunction with certain embodiments, it should be understood that the present disclosure is not limited to the disclosed embodiments, but rather, the present disclosure is intended to cover various improvements and equivalent arrangements included within the spirit and scope of the appended claims and their equivalents. Therefore, those of ordinary skill in the art will recognize that various changes and improvements may be made to the exemplary embodiments described herein without departing from the scope and spirit of the present disclosure, the disclosed embodiments, or the claimed embodiments.

[0068] The word "exemplary" is used herein to mean "serving as an example, instance, or illustration." Any embodiment described herein as "exemplary" is not necessarily to be construed as preferred or advantageous over other embodiments. Likewise, the term "embodiment" does not require that all embodiments include the discussed feature, advantage, or mode of operation.

[0069] Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings commonly understood by those of ordinary skill in the art. The nomenclature used in connection therewith and the techniques described herein are those known and commonly used in the art. Moreover, descriptions of well-known functions and structures are omitted for clarity and brevity.

[0070] Throughout this disclosure and the claims, the terms "about" and "substantially" are used as terms of approximation, rather than terms of degree, and reflect the inherent variations associated with measurement, important parameters, and interchangeability, all as understood by those of ordinary skill in the art. Moreover, it should be understood that throughout this disclosure and the appended claims, even if a numerical value is not preceded by the term "value," it is implicitly modified by that term unless otherwise indicated.

[0071] As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. It should also be understood that the terms "comprises", "comprising", "includes", "including", "have" and / or "having" when used herein specifically specify the presence of stated features, integers, actions, steps, operations, elements and / or components, but do not preclude the presence or addition of one or more other features, integers, actions, steps, operations, elements, components and / or groups thereof.

[0072] To be suitable for use as an active pharmaceutical ingredient (API), the RHI produced should have a high purity and low impurity profile, such as the RHI produced according to the method disclosed herein, which can produce a solid or liquid RHI API, all based on the total weight of the liquid or solid RHI API, respectively, with a purity of 99.0% (w / w) or higher, and total impurities (excluding the related substance deamidated Asn) A21 -RHI) is 0.8% or less, and impurity C is 0.1% (w / w) or less. In addition, the USP guidance on RHI states that the total impurities of RHI do not include the related substance deamidated Asn A21 -RHI.

[0073] As used herein, "total impurities" or "total impurities" refers to the total impurities other than the related substances deamidated Asn A21 -All impurities in RHI API outside RHI. Examples of the impurities included in the total impurities are the impurities shown in Table 1-2, but are not limited thereto. In a preferred embodiment, the "Total impurities" or "Total impurities" do not include additional impurities that may be generated and / or increased over time after the RHI API is combined with other components or formulated (such as in the case where the RHI API is formulated into a RHI finished drug product, the finished drug product is, for example, an aqueous solution for RHI injection).

[0074] "Highly purified recombinant human insulin API" or "highly purified RHI API" refers to a recombinant human insulin API in solid form or liquid form, whose total impurities are 0.8% (w / w) or less based on the total weight of the RHI API in solid or liquid form, respectively. For the sake of simplicity herein, RHI APIs with total impurities of 0.8% (w / w) or less based on the total weight of the RHI API are considered to be "highly purified RHI APIs". For example, RHI APIs (solid form or liquid form) with a purity of 99.0% (w / w) or more, total impurities of 0.8% (w / w) or less, and impurity C of 0.1% (w / w) or less based on the total weight of the RHI API are considered to be "highly purified RHI APIs".

[0075] Aspects of the embodiments of the present disclosure include methods for reducing a difficult-to-remove impurity referred to as impurity C. Impurity C specifically refers to acetylated lysine (lysine) at position 31 of the B chain of RHI. B31 , Lys B31 or K B31 ). Therefore, the "impurity C" used herein refers to the impurity C bound to the acetylated Lys B31 RHI, in which acetylated Lys B31 On the B chain with Thr B30 As described herein, Lys B31 Lys from C-peptide C1 . Acetylated Lys B31 Means Lys B31 The residue has an additional (-CO-CH3) group, as shown below:

[0076]

[0077] Acetylated lysine residues

[0078] Impurity C is generated by the impurity C precursor in the process of processing the single-chain precursor (SCP) into RHI. The synthesis (e.g., processing) of RHI includes an immature form of RHI known as a single-chain precursor (SCP) molecule, which is composed of an A-chain polypeptide and a B-chain polypeptide and a C-peptide located between them. Various recombinant forms of SCP molecules utilize various lengths of C-peptides, such as SCP sequences with structural formula I, II, or III. SCP sequences known in the art include C-peptide sequences from 1 amino acid residue to up to 35 (or more) amino acid residues. One operation of processing RHI API from SCP is to cut and remove C-peptide from A-chain and B-chain. However, in order to remove C-peptide, an enzyme cleavage operation is applied, which usually produces additional impurities due to the misdirected cleavage on a specific enzyme sensitive site. Therefore, the impurities that are difficult to remove in RHI processing may be different due to a specific C-peptide sequence.

[0079] The precursor of impurity C can be acetylated lysine in SCP C1 . The impurity C precursor may be generated during the synthesis of SCP, such as during fermentation, gene expression and / or inclusion body separation of SCP. Before SCP is processed into RHI, the impurity C precursor may be as high as about 2-3% (w / w) in the SCP batch. Subsequently, when SCP is processed into RHI, impurity C is generated during enzymatic cleavage (e.g., enzymatic digestion). Therefore, in some embodiments, in order to generate impurity C during enzymatic cleavage, a precursor of impurity C is generated during the synthesis of SCP, such as acetylated lysine in SCP. C1 Even after applying several purification operations during the processing of SCP into RHI, impurity C can still be as high as 0.7% (w / w) as an impurity in the final purified RHI API composition.

[0080] Impurity C may account for 0.5-0.7% (w / w) impurities in the final purified RHI API. Therefore, if the amount of impurity C in the final purified RHI composition is reduced to 0.1% (w / w) or less, the ability to produce a highly purified RHI API with a purity of 99.0% (w / w) or more and a total impurity of 0.8% (w / w) or less can be obtained. One reason why impurity C is difficult to remove is because its isoelectric point is about 5.40, which is similar to the isoelectric points of RHI and other impurities. In addition, impurity C is difficult to remove because it is resistant to CPB enzyme digestion. Another reason for the difficulty in removing impurity C is that, as described in the comparative example, conventional optimization of the purification operation cannot significantly reduce the amount of impurity C to 0.1% (w / w) or less based on the gross weight of the RHI API. Therefore, a technical solution for removing or significantly reducing impurity C is needed.

[0081] Thus, the present disclosure solves the technical problem by proposing a method for significantly reducing impurity C during the processing of SCP into RHI. In particular, the disclosed method significantly reduces the amount of impurity C to 0.1% (w / w) or less, and reduces the amount of total impurities to 0.8% (w / w) or less, based on the total weight of the RHI API.

[0082] Embodiments of the present disclosure introduce methods for producing RHI API in solid form, wherein the purity of the RHI API is 99.0% (w / w) or higher, and the total impurities are 0.8% (w / w) or lower, based on the total weight of the RHI API in solid form. In particular, embodiments of the present disclosure include methods for reducing impurity C to 0.1% (w / w) or lower during the processing of SCP into RHI, which in turn leads to the production of highly purified RHI API in solid form, wherein the purity is 99.0% (w / w) or higher, and the total impurities are 0.8% or lower, based on the total weight of the RHI API in solid form.

[0083] Another impurity that is difficult to remove is impurity E, namely Thr B30 Missing-RHI. RHI API can contain high concentrations of impurity E, typically greater than 0.3% (w / w). As previously described, the disclosed method can reduce impurity E to less than 0.20% (w / w). Impurity E can be generated during enzymatic digestion, such as during enzymatic cleavage operations 103 and 105 of method 100.

[0084] In some embodiments, the disclosed methods produce RHI APIs having a purity of about 99.0% (w / w), 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more based on the total weight of the RHI API. In some embodiments, the disclosed methods produce RHI APIs having a total impurity of about 0.8% (w / w), 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1% or less based on the total weight of the RHI API. In some embodiments, the disclosed methods reduce the impurity C in the RHI API to about 0.10% (w / w), 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01% or less based on the total weight of the RHI API.

[0085] As is generally understood in the art, "% (w / w)" means a percentage on a "weight per weight" or "weight by weight" basis. Throughout this disclosure, "%" is synonymous with and used interchangeably with "% (w / w)". For brevity throughout this disclosure, when "(w / w)" refers to RHI (i.e., highly purified RHI API, RHI API, RHI, Lys C1 -RHI, etc.), this means that "% (w / w)" or "%" is determined based on the weight of the target component divided by the total weight of the corresponding RHI. For example, an RHI with a purity of 99.0% or 99.0% (w / w) means that it has 99.0% RHI by weight (or mass) based on the total weight of the RHI, and 1.0% impurities by weight (or mass) based on the total weight of the RHI, wherein the 1.0% impurities by weight (or mass) include total impurities and related substances deamidated Asn A21 Alternatively, impurity C is 0.1% of RHI, meaning that it has 0.1% by weight (or mass) of impurity C based on the total weight of RHI, and the remaining 99.9% by weight (or mass) based on the total weight of RHI consists of RHI and other types of impurities (if any), such as total impurities and deamidated Asn A21 - RHI. Other types of impurities may include those listed in Tables 1 and 2.

[0086] Additionally, in the disclosed methods, the purity or percent impurity (w / w) relative to the total weight of a particular component at a particular time point can be evaluated at different time points. For example, the purity or percent impurity (w / w) can be evaluated after a column purification step. For example, after operation 109 of method 100, Lys C1 -The amount of impurity C in RHI is reduced to Lys C1 - 0.1% (w / w) or less of the total weight of RHI.

[0087] Human insulin is the unmodified human insulin present in natural human insulin. As known in the art, human insulin is a hormone that regulates glucose metabolism. It consists of two polypeptide chains, an A chain of 21 amino acids and a B chain of 30 amino acids, for a total of 51 amino acids. The A and B polypeptide chains are linked by a disulfide bond between the A chain cysteine ​​and the paired B chain cysteine. The disulfide bond and the corresponding cysteine ​​(Cys) are Cys A7 -Cys B7 、Cys A20 -Cys B19 and Cys A6 -Cys A11RHI is usually synthesized using recombinant DNA technology. RHI produced according to the methods disclosed herein is artificially produced RHI. Throughout this disclosure, "human insulin" or "insulin" may be used interchangeably and synonymously with "recombinant human insulin" or "RHI".

[0088] As described herein, human insulin consists of two polypeptide chains, an A chain of 21 amino acids and a B chain of 30 amino acids, for a total of 51 amino acids, A7 -Cys B7 、Cys A20 -Cys B19 and Cys A6 -Cys A11 There are three disulfide bonds between the cysteine ​​(Cys) in the B chain of human insulin or RHI from B1 to B 30 The amino acid sequence is FVNQHLCGSHLVEALYLVCGERGFFYTPKT (SEQ ID NO: 2). The A chain of human insulin or RHI is from A1 to A 2I It has the amino acid sequence GIVEQCCTSICSLYQLENYCN (SEQ ID NO: 1).

[0089] An "amino acid residue" or "residue" is one in which a hydroxyl group (ie, OH) has been removed from a carboxyl group (ie, COOH) and / or a hydrogen atom (ie, H + ) has had the amino group (i.e., NH2) removed.

[0090] As used herein, "cleavage," "digestion," "enzyme cleavage," "enzyme digestion," "cleaving," "digesting," "enzyme-cleaving," and similar terms refer to the breaking of bonds between amino acids in a peptide chain by an enzyme, such as carboxypeptidase B (CPB) or trypsin.

[0091] RHI is synthesized using a single-chain precursor (SCP) molecule commonly referred to as preproinsulin. "SCP" is interchangeable and synonymous with the term "preproinsulin". SCP generally includes a leader peptide sequence, an A chain with 21 amino acids, a B chain with 30 amino acids, and a C peptide connecting the A chain and the B chain consisting of 1-35 (or more) amino acids. The leader peptide sequence may also be referred to as a signal peptide. SCP can be synthesized using any suitable series of operations, including gene expression, fermentation, inclusion body separation, solubilization, and sulfonation. Common host cells used for SCP synthesis include Escherichia coli (E.coli), yeast, Bacillus subtilis (Bacillus subtilis), Salmonella (Salmonella) or other modified strains suitable for recombinant protein expression. Therefore, the SCP in the embodiments of the present disclosure can be produced by any suitable method known in the art. In some embodiments of the present disclosure, SCP is synthesized using the technology disclosed in Ferring. See European Patent No. EP0871474B1, entitled "Production of Human Insulin", filed on December 29, 1994, granted on March 1, 2007, the entire contents of which are incorporated herein by reference. In some embodiments of the present disclosure, Escherichia coli is used as the main host cell to synthesize SCP. In other embodiments of the present disclosure, yeast is used as the main host cell to synthesize SCP.

[0092] In some embodiments of the present disclosure, the SCP has a C-peptide consisting of 2 amino acids, arginine as X C2 and lysine as X C1 , where Arg C2 Gly attached to the A chain A1 , Lys C1 Thr connected to B chain B30 Amino acid abbreviations, such as "Arg" or "R" for arginine and "Lys" or "K" for lysine, are well known in the art and need not be described here for the sake of brevity. Typically, a C-peptide is a long peptide chain of about 32 amino acids or more. However, in a preferred embodiment, a C-peptide is a short peptide chain consisting of 2 amino acids, Arg. C2 -Lys C1 In this case, when Arg C2 -Lys C1 -RHI is cleaved to produce Lys C1 -RHI and impurity C, the C peptide was essentially cleaved in half.

[0093] In other embodiments, the C-peptide comprises Lys C1 , Arg C2 and Gly A1In other embodiments, the C-peptide is a short peptide chain comprising Lys C1 , Arg C2 and Gly A1 Arg bonded as the last residue of the C-peptide, wherein the short peptide chain consists of 10 amino acids or less, including 9 amino acids, 8 amino acids, 7 amino acids, 6 amino acids, 5 amino acids, 4 amino acids, 3 amino acids or 2 amino acids.

[0094] In some embodiments, the SCP molecule is represented by structural formula I:

[0095] Structural Formula I

[0096] (X n -X C末端 )-(X B1 -X B30 )-(X C1 -X C2 )-(X A1 -X A21 ).

[0097] According to structural formula I,

[0098] X n -X C末端 is a leader peptide sequence, in which:

[0099] X C末端 It is the same as Phe B1 The C-terminal residue of the leader peptide is bonded, and

[0100] X n Indicates that it is suitable for X C末端 Any number of amino acids used together as a leader peptide sequence. n -X C末端 is at least 1, 2, 3, 4 and at most 40, 50, 60, 70 (or more) amino acids. C末端 It's arginine.

[0101] According to structural formula I,

[0102] X B1 -X B30 It is the B chain of natural human insulin, and the amino acid sequence from amino acid residue 1 to amino acid residue 30 of the B chain is FVNQHLCGSHLVEALYLVCGERGFFYTPKT (SEQ ID NO: 2).

[0103] According to structural formula I,

[0104] X C1-X C2 is C-peptide, in which:

[0105] X C1 Lysine C1 ), and Lys C1 Thr of B chain B30 Bonding,

[0106] X C2 Arginine (Arg C2 ), and Arg C2 Gly A1 The amino acid sequence of the C-peptide is KR (SEQ ID NO: 3).

[0107] According to structural formula I,

[0108] X A1 -X A21 It is the A chain of natural human insulin, and the amino acid sequence from amino acid residue 1 to 21 of the A chain is GIVEQCCTSICSLYQLENYCN (SEQ ID NO: 1).

[0109] In some embodiments of the present disclosure, the SCP according to formula I comprises AX m The leader peptide sequence X of R n -X c-末端 , where the carboxyl end of R is connected to the Phe B1 Connect, and X m is any suitable number of amino acids, such as 1, 2, 3, 4 and up to 40, 50, 60 or 70 amino acids. Thus, an exemplary embodiment of SCP according to formula I has the following amino acid sequence: 5′AX m R-FVNQHLCGSHLVEALYLVCGERGFFYTPKT-KR-GIVEQCCTSICSLYQLENYCN 3′

[0110] In some embodiments of the present disclosure, SCP is represented by structural formula II:

[0111] Structural formula II

[0112] (X n -X C末端 )-(X B1 -X B30 )-(X C1 -X C2 -X C末端 )-(X A1 -X A21 ).

[0113] According to structural formula II,

[0114] X n -X C末端 is a leader peptide sequence, in which:

[0115] X C末端 It is the same as Phe B1 The C-terminal residue of the bonded leader peptide,

[0116] X n represents any number of amino acids suitable for use as a leader peptide sequence. n -X C末端 is at least 1, 2, 3, 4 and at most 40, 50, 60, 70 amino acids. In some embodiments, X C末端 It's arginine.

[0117] According to structural formula II,

[0118] X B1 -X B30 It is the B chain of natural human insulin, and the amino acid sequence from amino acid residue 1 to amino acid residue 30 of the B chain is FVNQHLCGSHLVEALYLVCGERGFFYTPKT (SEQ ID NO: 2).

[0119] According to structural formula II,

[0120] X C1 -X C2 -X C末端 is C-peptide, in which:

[0121] X C1 Lysine C1 ), Lys C1 Thr of B chain B30 Bonding,

[0122] X C2 Arginine (Arg C2 ),

[0123] X C末端 Arginine (Arg C3 ), Arg C3 Gly A1 Bonding.

[0124] According to structural formula II,

[0125] X A1 -X A21 It is the A chain of natural human insulin, and the amino acid sequence from amino acid residue 1 to 21 of the A chain is GIVEQCCTSICSLYQLENYCN (SEQ ID NO: 1).

[0126] In some embodiments, according to the SCP of formula II, the leader peptide sequence X n Contains at least AX as defined above m R, where Arg Xn The carboxyl terminus of the B chain B1 Connect, and X C1 -X C2 -X C末端 is KRR (SEQ ID NO: 4). Thus, an exemplary embodiment of SCP according to formula II has the following amino acid sequence: 5′AX m R-FVNQHLCGSHLVEALYLVCGERGFFYTPKT-KRR-GIVEQCCTSICSLYQLENYCN 3′

[0127] In some embodiments, SCP can be represented by structural formula III:

[0128] Structural formula III

[0129] (X n -X C末端 )-(X B1 -X B30 )-(KR-X Cn -R)-(X A1 -X A21 ).

[0130] In structure III, the C peptide consists of KR-X Cn -R means, where X Cn represents any suitable number of amino acids, such as up to 32 amino acids or more, and may include any amino acid except lysine, as well as all other permutations as defined in Structural Formulas I and II. Cn -R is KRQGR (SEQ ID NO: 5), wherein the C peptide contains Lys C1 , Arg C2 and Arg as the last residue of the C peptide, which is bound to Gly A1 Bonding.

[0131] In some embodiments of formula I, II or III, SCP further comprises a precursor of impurity C, such as acetylated lysine in peptide C. C1 , or any other precursor that may lead to impurity C. As discussed, the impurity C precursor may be generated during the SCP synthesis.

[0132] Embodiments of the present disclosure include synthesizing SCP according to any suitable expression method or synthesis technique. After synthesis, SCP (i.e., preproinsulin) can be treated (e.g., by enzymatic cleavage) to remove the leader peptide to produce proinsulin. In some embodiments, preproinsulin is digested with trypsin to remove the leader peptide sequence. After removing the leader peptide, such as Figure 2A As shown, proinsulin has an A chain, a B chain and a C peptide. Therefore, additional purification and enzymatic cleavage operations are applied to convert proinsulin into RHI by removing the C peptide and impurities.

[0133] A method for producing a highly purified RHI API having a purity of 99.0% or more, a total impurity of 0.8% or less, and an impurity C of 0.1% or less.

[0134] Embodiments of the present disclosure are directed to a method for processing SCP into a highly purified RHI API having a purity of 99.0% (w / w) or more, a total impurity of 0.8% (w / w) or less, and an amount of impurity C of 0.1% (w / w) or less based on the total weight of the RHI API. In a preferred embodiment, the highly purified RHI API is in solid form. In other embodiments, the highly purified RHI API is in liquid form, such as an aqueous form.

[0135] In some embodiments, such as Figure 1 The method 100 shown in FIG. 1 includes operations 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, and 111 for purifying RHI having a total weight purity of 99.0% (or higher) (w / w) based on the RHI API. The method 100 begins with an SCP having a structural formula I, II, or III. In this exemplary embodiment of the method 100, the SCP sequence has a structural formula I having a short C-peptide sequence of only two amino acids, Arg C2 -Lys C1 (as shown in SEQ ID NO: 3).

[0136] In operation 101, the SCP is renatured using a renaturation buffer known in the art. Operation 101 allows the SCP to renature to form Figure 2A The correct disulfide bonds present in native human insulin and RHI as shown in A7 -Cys B7 、Cys A20 -Cys B19 and Cys A6 -Cys A11 ).

[0137] At operation 102, a lysine protecting group (e.g., citraconic anhydride, tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz, Z), or allyloxycarbonyl (Alloc)) is applied to preproinsulin to protect the two lysine residues present in proinsulin. In this exemplary embodiment, the lysine residues of the proinsulin protein are present at Lys 2 of the C-peptide. C1 and Lys B29 . Figure 2A The protected Lys in the refolded proinsulin C1 and Lys B29 .

[0138] Operation 103 is the first enzymatic cleavage operation. In this exemplary embodiment of method 100, trypsin is applied to proinsulin. Figure 2B-2C As shown in Figure 2, trypsin cleaves: (i) Arg R1 and Phe B1 The peptide bond between (ii) Gly A1 and Arg C2 Therefore, after the first enzyme cleavage (i.e., enzyme digestion) operation, Figure 2B-2C As shown in R1 No longer with Phe B1 Bonding, Gly A1 No longer with Arg C2 Bonding. Even if Gly A1 No longer with Arg C2 Bonding, such as Figure 2B-2C As shown, due to Cys A7 -Cys B7 and Cys A20 -Cys B19 The A chain is still bonded to the B chain through the disulfide bond formed at the Figure 2D Proinsulin at the end of operation 103 is depicted. Figure 2D It is also shown that the Lys C1 and Lys B29 Still protected by the lysine protecting group.

[0139] In operation 104, a first column purification operation uses anion exchange column chromatography to remove Arg C2 -Lys C1 -RHI separated from the leader peptide sequence. The term "Arg C2 -Lys C1"Arg-RHI", "Arg(C2)-Lys(C1)-RHI", "Arg-Lys-RHI", "Arg-Lys-insulin" and "Arg-Lys-RHI" each have the same meaning and are used interchangeably herein to refer to the insulin of formula I and II having arginine at position 2 (X C2 ) and lysine at position 1 (X C1 ) of human insulin A chain and B chain of C peptide. In operation 104, other impurities may also be separated or reduced. Column chromatography, such as anion exchange column chromatography, is known in the art for separating a target protein from a solution mixture and / or reducing impurities associated with the target protein.

[0140] In anion exchange column chromatography, the ion exchange resin contains positively charged groups (i.e., cations), which in turn bind to negatively charged molecules. Anion exchange column chromatography can be performed at higher pH levels, particularly at a pH above the isoelectric point of the target peptide, so that the target protein has a negative charge and will bind to the positively charged resin. Therefore, at the end of operation 104, the batch that continues to the next operation mainly contains Arg-Lys-RHI and impurities.

[0141] Operation 105 includes a second enzymatic cleavage operation. In operation 105, carboxypeptidase B (CPB) is applied to Arg-Lys-RHI. CPB is particularly effective for enzymatic cleavage of peptide bonds of basic amino acids such as arginine and lysine. In operation 105, in some embodiments, CPB is applied to Arg-Lys-RHI at a concentration of about 1 / 10000 (w / w) of protein. In operation 105, in some embodiments, CPB can be applied at a pH in the range of about 7.0 to about 10.0, about 7.0 to about 8.0, about 7.5 to about 8.5, about 8.0 to about 9.0, about 8.5 to about 9.5, or about 9.0 to about 10.0. In operation 105, in some embodiments, CPB can be applied at a temperature in the range of about 22°C to about 28°C, about 23°C to about 27°C, or about 24°C to about 26°C. At operation 105, in some embodiments, CPB may be applied for at least about 1, 2, 3, 4, 5, 6, or more hours.

[0142] like Figure 2E As shown, because in (X C1 ) is still protected, and CPB only cleaves Arg C2 and Lys C1 The peptide bond between C1 -RHI and unbound Arg C2 In the C-peptide, only Arg C2 -Lys C1In the embodiment of a short peptide composed of , the enzymatic cleavage operation 105 essentially cuts the C peptide in half. C2 It can be removed in operation 108 as described below. C1 "-RHI", "Lys(C1)-RHI", "Lys-RHI", "Lys-insulin" and "Lys-RHI" each have the same meaning and are used interchangeably herein to refer to a C2 Human insulin, which has been cleaved from Arg-Lys-RHI to form the A-chain and B-chain polypeptides, has a lysine residue in the C-peptide that is attached to the threonine residue at position 30 of the B-chain. B30 ) bonding.

[0143] Referring to operation 105, the result of adding CPB to the Arg-Lys peptide is the generation of impurity C. With the generation of impurity C in operation 105, the technical challenge becomes the removal of impurity C from Lys-RHI.

[0144] Continuing with operation 105, since the C-peptide has only two amino acid residues, this operation effectively cuts the C-peptide in half, such as Figure 2E As shown. This is different from the method in which the C-peptide is cleaved in its entirety in a single enzymatic cleavage operation. The motivation for cleaving the entire C-peptide (e.g., two or all amino acids) in a single enzymatic cleavage operation is to avoid additional impurities introduced by multiple enzymatic operations, which is contrary to the goal of producing highly purified RHI. Moreover, additional impurities would require additional purification operations, which reduces the yield and makes the overall preparation process more complicated. Therefore, previous methods all cleave the entire C-peptide with one digestion operation.

[0145] Although the present disclosure and the methods according to the embodiments of the present disclosure are not bound by any particular theory, the method (e.g., 100) unexpectedly produces an RHI API having an impurity C of 0.1% (w / w) or less by using additional enzymatic digestion operations 105 and 109 in combination with enzymatic cleavage of the C peptide, which enables the production of a highly purified solid form of the RHI API having a purity of 99.0% (w / w) or more and total impurities of 0.8% (w / w) or less based on the total weight of the solid form of the RHI API. According to the embodiments of the present disclosure, by increasing the number of enzymatic cleavage operations, the amount of impurity C in the RHI API can be reduced to 0.1% (w / w) or less.

[0146] Referring to operation 106, Lys in the Lys-RHI C1 and Lys B29 The lysine residue at is deprotected by removing the lysine protecting group. Figure 2F As shown, the Lys in the Lys-RHI C1 and LysB29 The lysine residue at that position is now susceptible to cleavage by enzymatic digestion.

[0147] In some embodiments, referring to operation 107 , aprotinin can be optionally applied to the deprotected Lys-RHI to remove residual trypsin from operation 103 .

[0148] Operation 108 is a second column purification operation, which separates Arg from Lys-RHI based on charge using anion exchange column chromatography. C2 and other impurities. In operation 108, the one or more impurities separated may include those well known in the art and the impurities identified herein, including the impurities shown in Tables 1-6. It is worth noting that the separation of the impurities may include the type of impurities, the amount of impurities, or a combination thereof. In some embodiments, in operation 108, anion exchange column chromatography is performed using a pH in the range of 7.0 to 9.5 or any range contained therein, the range includes but is not limited to 7.0 to 9.0, 7.0 to 8.5, 7.0 to 8.0, 7.0 to 7.5, 7.5 to 9.0, 7.5 to 8.5, 7.5 to 8.0, 8.0 to 9.5, 8.0 to 9.0, or 8.0 to 8.5. In other embodiments, at operation 108, anion exchange column chromatography is performed using a pH in the range of about 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, or 9.5.

[0149] At the end of operation 108 , the batch continuing to the next operation mainly contains Lys-RHI and impurities not removed in operation 108 , such as impurity C.

[0150] Operation 109 is the third column purification operation. Prior to operation 109, the batch had NMT (not more than) 20% (w / w) impurities. Operation 109 uses reverse phase high performance liquid chromatography (RP-HPLC) using a C18 phase column. It is worth noting that other phase column specifications, such as a C8 phase column, can also be used in operation 109. In some embodiments, RP-HPLC may also include a semi-preparative column, a preparative column, or a combination thereof. In some embodiments, the semi-preparative column is a column having a length of about 250 mm and an inner diameter of about 10.0 mm, as shown in Table 1. In some embodiments, the preparative column is a column having a length of about 250 mm and an inner diameter of about 21.2 mm. In other embodiments, the preparative column is a column having a length of about 350 mm and an inner diameter of about 100 mm. The C18 phase column can adopt a particle size of 3μm to 50μm (or any range included therein), for example 3μm, 5μm, 10μm, 15μm, 20μm, 25μm, 30μm, 35μm, 40μm, 45μm or 50μm.

[0151] At operation 109, impurity C and other impurities are separated from Lys-RHI using the C18 phase column and the RP-HPLC process based on their respective hydrophobicity. At operation 109, in some embodiments, the column chromatography is performed using a mixture of water or an aqueous buffer (e.g., (NH4)2SO4) and an organic solvent such as isopropanol (IPA) as a mobile phase. At operation 109, in some embodiments, the column chromatography is performed using a pH in the range of about 1.5 to about 3.5 or any range contained therein, including but not limited to about 2.0 to about 3.0, about 2.5 to about 3.0, about 3.0 to about 3.5, about 2.2 to about 2.8, or about 2.5 to about 3.0. In some embodiments, at operation 109, the column chromatography is performed using a pH of about 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, or 3.5. Other impurities may also be separated or reduced at operation 109.

[0152] At the end of operation 109, the batch that continues to the next operation mainly contains Lys-RHI and about 0.10% (w / w) or less of impurity C (acetylated Lys-RHI). The column purification operation 109 combined with the enzyme digestion operation 105 unexpectedly produces Lys-RHI containing 0.1% (w / w) or less of impurity C based on the total weight of Lys-RHI, thereby ultimately producing a highly purified RHI API having 0.1% (w / w) or less of impurity C based on the total weight of the highly purified RHI API.

[0153] The process of described RP-HPLC can comprise any suitable silica-based resin. Non-limiting examples of silica-based resins for RP-HPLC include C18 resin, which includes 18 carbon atoms as stationary phase. In some embodiments, carbon molecules of other specifications can also be adopted in the post, such as C4 (4 carbon atoms), C5 (5 carbons), C6 (6 carbon atoms), C8 (8 carbon atoms), C12 (12 carbon atoms), C16 (16 carbon atoms), C18 (18 carbon atoms) and C20 (20 carbon atoms). Except carbon-bonded silica, pure silica, cyano-bonded silica, phenyl-bonded silica and other suitable silica can also be used in RP-HPLC.

[0154] In other embodiments, the RP-HPLC has an inner diameter of about 50 mm, 100 mm, 200 mm, 300 mm, 400 mm, 500 mm, 600 mm or more, depending on the scale required for commercial production of the RHI API. In still other embodiments, the RP-HPLC column length is about 200 mm, 250 mm, 300 mm, 350 mm, 400 mm, 450 mm, 500 mm, 550 mm, 600 mm or more, depending on the scale required for commercial production of the RHI API.

[0155] Operation 110 is the third enzyme cleavage operation. In operation 110, because Lys is no longer protected, CPB can cleave Lys C1 and Thr B30 The peptide bonds between Figure 2G As shown, the C peptide (Lys C1 residues), and generate RHI. At the end of operation 110, RHI is as Figure 2H Optionally, at operation 110, the RP-HPLC can be diluted with water to further reduce impurity E. For example, the RP-HPLC can be diluted 2x, 3x, 4x or more to reduce impurity E, as shown in Example 9.

[0156] Operation 111 is the fourth column purification operation. Operation 111 uses reverse phase high performance liquid chromatography (RP-HPLC) using a C18 column to remove Lys C1and other impurities to produce a highly purified RHI having a total impurity of 0.8% (w / w) or less. At operation 111, the one or more impurities separated may include those known in the art and the impurities identified herein, including the impurities identified in Tables 1-6. It is noteworthy that the separation of impurities may include the type of impurity, the amount of impurity, or a combination thereof. It is noteworthy that other phase column specifications may also be used for operation 111, such as a C8 phase column. In some embodiments, at operation 111, RP-HPLC is performed using a pH in the range of about 1.5 to about 3.5 or any range contained therein, including but not limited to about 2.0 to about 3.0, about 2.5 to about 3.0, about 3.0 to about 3.5, about 2.2 to about 2.8, or about 2.5 to about 3.0. In some embodiments, at operation 109, column chromatography is performed using a pH of about 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, or 3.5. At the end of operation 111, highly purified RHI is produced in liquid form, which is suitable for use as an API.

[0157] After operation 111, method 100 further includes a crystallization operation ( Figure 1 ), by adopting any suitable crystallization technique (such as applying zinc and vacuum drying) to produce RHI in solid form. After operation 111, the highly purified RHI is in solid form.

[0158] Therefore, as shown in Examples 1-8 below, the method 100 produces a highly purified RHI API having a purity of 99.0% (w / w) or more, a total impurity of 0.8% (w / w) or less, and an impurity C of 0.1% (w / w) or less, based on the total weight of the highly purified RHI API. In addition, as shown in Examples 1-4 and 7-8, the method 100 can produce a RHI API having a purity of 99.0% (w / w) or more, a total impurity of 0.8% (w / w) or less, an impurity C of 0.1% (w / w) or less, and a total impurity E of 0.2% (w / w) or less, all based on the total weight of the highly purified RHI API. This highly purified RHI is suitable for use as an API due to its high purity and low impurity characteristics. In addition, the RHI API is in a solid form.

[0159] Example

[0160] Examples 1-4: The disclosed process produces highly purified RHI API with a purity of 99.0% or higher, total impurities of 0.8% or lower, and impurity C of 0.1% or lower.

[0161] As shown in Table 1 below, Examples 1-4 use method 100 to produce a highly purified RHI API in solid form having a purity of 99.0% (w / w) or higher, a total impurity of 0.8% (w / w) or lower, and an impurity C of 0.1% (w / w) or lower, based on the total weight of the highly purified RHI API in solid form. In Table 1, the total impurities include impurity C, impurity X4, impurity D, impurity E, and impurity Z. The total impurities do not include the related substance deamidated Asn A21 -RHI. Table 2 identifies the types of RHI impurities identified in Table 1, the purity and percentage of impurities based on w / w of the total weight of the highly purified solid RHI API used. In Table 1, the purity and percentage of impurities (w / w) of the solid RHI API were evaluated soon after the purified RHI API was crystallized into a solid form.

[0162] Moreover, unexpectedly, in Examples 1-4, method 100 reduces the amount of impurity E to 0.2% (w / w) or less, as low as 0.12% (w / w), with an average of 0.15% (w / w) or less. Notably, without using the optional water dilution step in operation 110 of method 100, Examples 1-4 unexpectedly reduce the amount of impurity E.

[0163] Table 1 - Impurity profile of Examples 1-4 - Highly purified RHI API in solid form

[0164]

[0165]

[0166] In Table 1, nd means not detected and / or <0.05%.

[0167] Table 2 - Impurities identified in Table 1

[0168] RHI-Impurity Type Identity Impurity C <![CDATA[Acetylated Lys B31 -RHI]]> Impurity X4 Unidentified* Impurity D Methylated-RHI Impurity E <![CDATA[Thr B30 Missing-RHI]]> Impurity Z High molecular weight product (HMWP) - dimer or polymer Impurity B+X Impurity B is Lys-RHI and Impurity X is the peak within Impurity B.

[0169] *Impurity X4 was not identified because the impurity was less than 0.10% (w / w). FDA does not usually require impurity identification when the impurity is less than 0.1% (w / w).

[0170] To illustrate the significant technical advances achieved by the present disclosure, Comparative Examples 1-3 are provided below to show that conventional purification techniques cannot produce highly purified RHI APIs having a purity of 99.0% (w / w) or higher, total impurities of 0.8% (w / w) or lower, and impurity C of 0.1% (w / w) or lower, based on the total weight of the highly purified RHI API.

[0171] Comparative Example 1 - Another method for preparing RHI of lower purity.

[0172] Comparative Example 1 is another method for producing RHI API, and Figure 3 The method 300 is provided. Figure 3 As shown, operation 301 is to refold the preproinsulin using a refolding buffer. Comparative Example 1 is based on RHI produced using at least some of the methods disclosed in Ferring.

[0173] At operation 302, a lysine protecting group, such as citraconic anhydride, tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz, Z), or allyloxycarbonyl (Alloc), is applied to proinsulin to protect the lysine residues present in proinsulin, which are Lys of the C-peptide. C1 and Lys B29 .

[0174] Operation 303 is the first enzymatic cleavage operation. In operation 303, trypsin is applied to proinsulin. In operation 303, trypsin cleaves: (i) Arg R1 and Phe B1 The peptide bond between (ii) Gly of chain A A1 and Arg C2 Thus, after this first enzyme digestion operation, Arg R1 No longer with Phe B1 Bonding, Gly A1 No longer with Arg C2 However, even if Gly A1 No longer with Arg C2 Bonding, as described in renaturation operation 301, due to the Cys A7 -Cys B7 and Cys A20 -Cys B19 The A chain is still bonded to the B chain through the disulfide bond formed at the

[0175] Operation 304 is a first column purification operation. In operation 304, the first column purification operation is anion exchange column chromatography to remove Arg C2 -Lys C1 Therefore, at the end of operation 304, the batch that continues to enter the next operation mainly contains Arg-Lys-RHI and impurities.

[0176] In operation 305, the lysine protecting group is removed to obtain a lysine residue. C1 and Lys B29 Therefore, the lysine residue at LysC1 and Lys B29 The lysine residue at the position is no longer protected and is susceptible to enzyme cleavage.

[0177] Optionally, at operation 306 , aprotinin is applied to eliminate residual trypsin from operation 303 .

[0178] Operation 307 is a second column purification operation, which is an anion exchange column chromatography to separate C peptide from RHI. At the end of operation 307, the batch continuing to the next operation mainly contains RHI and impurities, such as impurity C.

[0179] Operation 308 is the second enzyme cleavage operation. In operation 308, because Lys is no longer protected, CPB cleaves Lys C1 and Thr B3 The peptide bond between the two chains is broken, thereby separating the C peptide from the B chain and producing RHI.

[0180] Operation 309 is the third column purification operation. In operation 309, reverse phase high performance liquid chromatography (RP-HPLC) using a C18 column is used to remove C-peptide and other impurities to produce RHI. RHI is then crystallized into a solid form.

[0181] Method 300 can only obtain such a solid form of RHI API, which has a purity of about 97.8% (w / w), total impurities of about 1.7%, impurity C of about 0.5%-0.8% (w / w), and impurity E of about 0.3%-0.5% (w / w), based on the total weight of the RHI API. In Comparative Example 1, the purity and impurity percentage (w / w) of the solid RHI API were evaluated soon after the RHI API was crystallized into a solid form.

[0182] Obviously, process 300 is different from process 100 because process 100 includes an enzyme digestion operation 105 and a column purification operation 109, both of which produce the unexpected and surprising result of reducing impurity C to 0.1% (w / w) or less, which in turn enables the production of highly purified RHI having a purity of 99.0% (w / w) or greater and total impurities of 0.8% (w / w) or less based on the total weight of the highly purified RHI API. In addition, process 100 reduces the amount of impurity E to 0.2% (w / w) or less.

[0183] Table 3 - Comparison of Examples 1-4 (average values) with Comparative Example 1

[0184]

[0185]

[0186] In Table 3, the purity characteristics of the RHI APIs of Examples 1-4 are averaged and compared with the purity characteristics of Comparative Example 1. Notably, as shown in Table 3, Examples 1-4 have total impurities of about 0.33% (w / w), which is significantly lower than the total impurities of about 1.73% (w / w) of Comparative Example 1. In Table 3, the percentages of purity and impurities are based on w / w, more specifically based on w / w using the total weight of the corresponding RHI API.

[0187] Comparative Example 2 - Another method for preparing RHI API of lower purity.

[0188] Comparative Example 2 Figure 4 400. It is worth noting that the difference between Comparative Examples 1-2 is mainly due to the addition of column purification operation 407. Therefore, in method 400, operations 401-406 are equivalent to operations 301-306, and operations 408-410 are equivalent to operations 307-309, so for the sake of brevity, there is no need to describe them again. Similar to operation 309, column purification operation 407 is RP-HPLC using a C18 column. RHI is crystallized into a solid form. In Comparative Example 2, after the RHI API is crystallized into a solid form, the purity and impurity percentage (w / w) of the solid RHI API are quickly evaluated.

[0189] Obviously, even though several column purification operations are performed in method 400, method 400 cannot produce a highly purified RHI API in a solid form having a purity of 99.0% (w / w) or more and an impurity C of 0.1% (w / w) or less based on the total weight of the highly purified RHI API. Instead, method 400 produces a RHI API in a solid form having a purity of about 98.1% (w / w), total impurities of about 73% (w / w), and impurity C of about 0.5-0.7% (w / w), based on the total weight of the RHI API.

[0190] Comparative Example 3 - Another method for preparing RHI API of lower purity.

[0191] Comparative Example 3 Figure 5In the method 500 provided. It is noteworthy that the difference between Comparative Examples 1 and 3 is mainly the switching of anion exchange column operation (operation 509 and 307), RP-HPLC operation (operation 507 and 309). Therefore, in method 500, operations 501-506 are equivalent to operations 301-306, operation 507 is equivalent to operation 309, operation 508 is equivalent to operation 308, and operation 509 is equivalent to operation 307, so for the sake of brevity, there is no need to describe again. Method 500 cannot produce a highly purified RHI API in solid form, based on the total weight of the highly purified RHI API, with a purity of 99.0% (w / w) or more and an impurity C of 0.1% (w / w) or less. On the contrary, based on the total weight of the RHI API, method 500 produces a solid form of RHI API with a purity of about 96.5% (w / w) and an impurity C of about 0.5-0.7% (w / w). In Comparative Example 3, the purity and impurity percentage (w / w) of the solid RHI API were evaluated soon after the RHI API was crystallized into solid form.

[0192] Obviously, Comparative Examples 1-3 show that conventional optimization of column purification operation does not solve the technical problem of significantly reducing impurity C in RHI API. On the contrary, as disclosed in method 100, the unique combination of enzymatic digestion operation 105 and column purification operation 109 plays an important role in producing highly purified RHI API in solid form, with a purity of 99.0% (w / w) or more, total impurities of 0.8% (w / w) or less, and impurity C of 0.1% (w / w) or less based on the total weight of the highly purified RHI API in solid form.

[0193] Comparative Example 4-" R”RHI

[0194] “ R" RHI is a commercially available RHI used as Comparative Example 4. In Comparative Example 4, four batches of " The purity characteristics of R"RHI are shown in Table 4 and compared with Examples 1-4.

[0195] Table 4 - Examples 1-4 (average value) and " R” RHI Comparison

[0196]

[0197] Obviously, as shown in Table 4, Examples 1-4 have about 0.33% total impurities, which is significantly lower than the four batches of " The R" RHIs averaged about 1.65% (w / w) total impurities. In Table 4, the purity and percentage of impurities are based on w / w of the total weight of the corresponding RHI API used.

[0198] Examples 5-8: Scale-up examples of high purity RHI API in solid form.

[0199] To demonstrate the ability of the method 100 in a scaled-up environment, such as large-scale manufacturing, the method 100 was applied to a 100 mm x 350 mm column, as shown in Examples 5-8 in Table 5. See Table 2 for a description of the impurities in Table 5. In Table 5, the purity and impurity percentage (w / w) of the RHI API were evaluated shortly after the purified RHI API was crystallized into a solid form.

[0200] Table 5 - Impurity profile of scaled-up Examples 5-8 - highly purified RHI API in solid form.

[0201]

[0202]

[0203] In Table 5, nd means not picked up and / or < 0.05%.

[0204] As shown in the enlarged examples 5-8 in Table 5, the method 100 produces a highly purified RHI API in solid form with a purity of 99.0% (w / w) or more, a total impurity of 0.8% (w / w) or less, and an impurity C of 0.1% (w / w) or less, based on the total weight of the highly purified RHI API in solid form. Moreover, examples 7-8 reduce the amount of impurity E to 0.20% (w / w). It is noteworthy that without using the optional water dilution step in operation 110 of the method 100, examples 7-8 unexpectedly reduce the amount of impurity E. However, as shown in Example 9, using the optional water dilution step in operation 110 of the method 100 can further reduce the amount of impurity E.

[0205] Example 9 - Further reduction of the amount of impurity E.

[0206] Optionally, at operation 110, the RP-HPLC can be diluted with water to further reduce impurity E. For clarity, Example 9 shown in Table 6 is a study in which water dilution was applied to RP-HPLC at operation 110, and three (3) samples were diluted 2 times (2x), 3 times (3x), or 4 times (4x). As shown in Table 6, as the water dilution factor in operation 110 increases, the percentage of impurity E decreases. Therefore, if Examples 1-8 utilize this optional water dilution step in operation 110 of method 100, the amount of impurity E can be further reduced.

[0207] Table 6 - Further reduction of impurity E.

[0208] A composition for a highly purified RHI API having a purity of 99.0% or more, a total impurity of 0.8% or less, and an impurity C of 0.1% or less.

[0209] Also disclosed is a composition for an active pharmaceutical ingredient (API) comprising highly purified recombinant human insulin (RHI) having a purity of 99.0% (w / w) or higher, a total impurity of 0.8% (w / w) or lower, and an impurity C of 0.1% (w / w) or lower, based on the total weight of the highly purified RHI API, wherein w / w represents the weight to weight ratio of the highly purified RHI API. As disclosed herein, the total impurities do not include the related substance deamidated Asn A21 -RHI, impurity C is acetylated Lys B31 - RHI. Examples 1-8 provide exemplary embodiments of such compositions.

[0210] Additionally, in other embodiments of the composition, the purity of the highly purified RHI API is 99.0% (w / w) or higher, the total impurities are 0.8% or lower, the impurity C is 0.1% (w / w) or lower, and the impurity E is 0.2% (w / w) or lower, based on the total weight of the highly purified RHI API. Examples 1-4 and 7-8 provide exemplary embodiments of such compositions.

[0211] In some embodiments of the composition, the purity of the highly purified RHI API is 99.3% (w / w) or higher based on the gross weight of the highly purified RHI API. In some embodiments, the highly purified RHI API composition is in solid form. In other embodiments, the highly purified RHI API composition is in liquid form, such as an aqueous form. Exemplary embodiments of these API compositions are provided in Examples 1-8, and these API compositions can be produced using method 100.

[0212] The disclosed highly purified API RHI composition will provide a basis for developing recombinant human insulin drug products with high purity and fewer impurities, such as recombinant human insulin drug preparations for subcutaneous injection or intravenous injection.

[0213] Sequence Listing

[0214] Number of sequences: 5

[0215] SEQ ID NO 1

[0216] Length: 21

[0217] Category: PRT

[0218] Organisms: Artificial sequences

[0219] feature:

[0220] Additional information: Description of the artificial sequence: natural human insulin A chain.

[0221] Sequence: 1:

[0222]

[0223] SEQ ID NO2

[0224] Length: 30

[0225] Category: PRT

[0226] Organisms: Artificial sequences

[0227] feature:

[0228] Additional information: Description of the artificial sequence: natural human insulin B chain.

[0229] Sequence:2:

[0230]

[0231] SEQ ID NO 3

[0232] Length: 2

[0233] Category: PRT

[0234] Organisms: Artificial sequences

[0235] feature:

[0236] Additional information: Description of artificial sequence: C-peptide

[0237] Sequence:3:

[0238]

[0239] SEQ ID NO4

[0240] Length: 3

[0241] Category: PRT

[0242] Organisms: Artificial sequences

[0243] feature:

[0244] Additional information: Description of artificial sequence: C-peptide

[0245] Sequence:4:

[0246]

[0247] SEQ ID NO 5

[0248] Length: 5

[0249] Category: PRT

[0250] Organisms: Artificial sequences

[0251] feature:

[0252] Additional information: Description of artificial sequence: C-peptide

[0253] Sequence:5:

[0254]

Claims

1. A method for producing highly purified recombinant human insulin RHI active pharmaceutical ingredient API, the method comprising: Two lysine residues on the single-chain precursor SCP were protected with lysine protecting groups, wherein the SCP had a structural formula of [(leader peptide)-(B chain)-(C peptide)-(A chain)], wherein the C peptide was composed of Arg C2 -Lys C1 The two lysine residues are the first lysine residue (Lys C1 ), and the second lysine residue at residue 29 (B29) of the B chain of the SCP (Lys B29 ); The SCP is cleaved to produce Arg C2 -Lys C1 - RHI, wherein enzymatic cleavage of the SCP comprises applying trypsin to the SCP; A first column purification operation was applied to remove the Arg C2 -Lys C1 -RHI to separate the leader peptide, thereby generating Arg C2 -Lys C1 -RHI, wherein the first column purification operation uses anion column chromatography; The Arg C2 -Lys C1 -C peptide in RHI to generate Lys C1 -RHI and impurity C, wherein the impurity C is acetylated Lys B31 -RHI, wherein the half-cleavage of the C-peptide comprises the addition of the Arg C2 -Lys C1 - RHI application of carboxypeptidase B CPB; Make the Lys C1 - Deprotection of the two lysine residues in RHI; removing the trypsin using aprotinin; A second column purification operation was applied to remove the Lys C1 - separating one or more impurities from RHI, wherein the second column purification operation uses anion column chromatography; For the Lys C1 -RHI applies a third column purification operation to remove the Lys C1 -The amount of impurity C in RHI is reduced to C1 -0.1% w / w or less of the total weight of RHI, wherein the third column purification operation comprises the application of reverse phase high performance liquid chromatography RP-HPLC; Enzyme cleavage of the Lys C1 -RHI to generate Lys C1 and the RHI, wherein the enzyme cleaves the Lys C1 - RHI includes the use of CPB; applying a fourth column purification operation to separate one or more impurities from the RHI, thereby producing highly purified RHI for use as an API, wherein the fourth column purification operation comprises applying RP-HPLC; and crystallizing the highly purified RHI API to produce a highly purified RHI API in solid form; wherein the process produces a highly purified RHI API in a solid form having a purity of 99.0% w / w or greater and a total impurity of 0.8% w / w or less, wherein the total impurity does not include deamidated Asn A21 -RHI, and the impurity C is 0.1% w / w or less, wherein w / w means weight to weight and is based on the total weight of the highly purified RHI API in solid form.

2. The method of claim 1, wherein: The highly purified RHI API in solid form has a purity of 99.3% w / w or higher and a total impurity of 0.5% w / w or lower, excluding deamidated Asn A21 -RHI, and the impurity C is 0.1% w / w or less.

3. The method of claim 1, wherein: Enzyme cleavage of the Arg C2 -Lys C1 The step of -RHI comprises adding Arg C2 -Lys C1 - RHI applies the CBP.

4. The method of claim 1, wherein: The third column purification operation to reduce the amount of the impurity C to 0.1% w / w or less comprises applying reverse phase high performance liquid chromatography RP-HPLC using a C18 column to separate the Lys C1 - Separation of the impurity C from RHI.

5. The method of claim 4, wherein: The third column purification operation of reducing the amount of the impurity C to 0.1% w / w or less further comprises employing an aqueous solution in the RP-HPLC, the aqueous solution comprising (NH4)2SO4, isopropyl alcohol (IPA) or a combination thereof.

6. The method of claim 4, wherein: The third column purification operation of reducing the amount of the impurity C to 0.1% w / w or less is performed at a pH of about 2.5 to about 3.

0.

7. The method of claim 4, wherein: The RP-HPLC uses a preparative column.

8. The method of claim 4, wherein: The RP-HPLC uses a semi-preparative column.

9. The method of claim 1, wherein: The third column purification operation and the fourth column purification operation each employed RP-HPLC with a C18 column.

10. The method of claim 1, wherein: The third column purification operation and the fourth column purification operation each employed RP-HPLC with a C8 column.

11. The method of claim 1, wherein: The lysine protecting group comprises citraconic anhydride, tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz, Z), allyloxycarbonyl (Alloc) or a combination thereof.

12. The method of claim 1, further comprising renaturing the SCP using a renaturation buffer.

13. The method of claim 1, wherein: The one or more impurities separated in the second column purification operation include at least Arg C2 .

14. The method of claim 1, wherein: The one or more impurities separated in the fourth column purification operation include at least Lys C1 .

15. The method of claim 1, wherein: The method further reduces the amount of impurity E to 0.2% w / w or less, wherein the impurity E is Thr B30 Delete-RHI, thereby producing a highly purified RHI API having a purity of 99.0% w / w, total impurities of 0.8% w / w or less, impurity C of 0.1% w / w or less, and impurity E of 0.2% w / w or less, based on the total weight of the highly purified RHI API in solid form or liquid form, respectively.